Published in Antimicrob Agents Chemother on June 01, 1990
Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother (1994) 3.96
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 2.84
In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother (1993) 2.18
In vitro activity of T-3761, a new fluoroquinolone. Antimicrob Agents Chemother (1992) 2.10
In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chemother (1992) 1.64
In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob Agents Chemother (1992) 1.61
Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci. Antimicrob Agents Chemother (1992) 1.52
Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother (1991) 1.42
Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells. Antimicrob Agents Chemother (1992) 1.37
Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1991) 1.32
Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1991) 1.21
Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis. Antimicrob Agents Chemother (1991) 1.17
In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. Antimicrob Agents Chemother (1990) 1.12
Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin. Antimicrob Agents Chemother (1998) 0.88
Pharmacokinetics of sparfloxacin in patients with renal impairment. Antimicrob Agents Chemother (1994) 0.88
In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients. Antimicrob Agents Chemother (1992) 0.86
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol (1984) 14.64
Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1985) 8.66
Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother (1984) 6.81
Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet (1988) 6.30
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother (1986) 6.20
Occurrence of a beta-lactam-inducible penicillin-binding protein in methicillin-resistant staphylococci. Antimicrob Agents Chemother (1985) 6.19
Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother (1986) 6.03
Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother (1986) 6.00
Antimicrobial resistance of Staphylococcus aureus: genetic basis. Microbiol Rev (1987) 6.00
Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet (1986) 5.95
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother (1989) 4.79
In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother (1989) 4.38
gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob Agents Chemother (1989) 3.67
New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity. J Bacteriol (1981) 3.65
Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob Agents Chemother (1989) 2.99
Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother (1989) 2.80
Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1985) 2.58
Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations. Antimicrob Agents Chemother (1989) 1.34
Ciprofloxacin: in vitro activity, mechanism of action, and resistance. Rev Infect Dis (1988) 1.14
In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother (1980) 26.28
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections. Antimicrob Agents Chemother (1981) 8.59
Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection (1984) 7.53
In vitro and in vivo antibacterial activity of T-1220, a new semisynthetic penicillin. Antimicrob Agents Chemother (1977) 7.35
Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia. Antimicrob Agents Chemother (1982) 7.11
Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1991) 7.10
CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet (1994) 7.07
Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus. J Bacteriol (1986) 6.97
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell (1994) 6.45
Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother (1986) 6.03
Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother (1986) 6.00
The purification and properties of penicillin beta-lactamases mediated by transmissible R factors in Escherichia coli. J Biochem (1969) 5.35
Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 4.96
Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation (1983) 4.70
In vitro antibacterial activity of cefoperazone (T-1551), a new semisynthetic cephalosporin. Antimicrob Agents Chemother (1979) 4.49
In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother (1989) 4.38
Purification and properties of a new beta-lactamase from Pseudomonas cepacia. Antimicrob Agents Chemother (1980) 4.09
In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother (1987) 3.84
In vitro and in vivo antibacterial activity of AT-2266. Antimicrob Agents Chemother (1983) 3.80
Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli. Antimicrob Agents Chemother (1986) 3.69
Antibacterial activity of apalcillin (PC-904) against gram-negative bacilli, especially ampicillin-, carbenicillin-, and gentamicin-resistant clinical isolates. Antimicrob Agents Chemother (1978) 3.65
Biochemical properties of beta-lactamase produced by Flavobacterium odoratum. Antimicrob Agents Chemother (1985) 3.62
Properties of novel beta-lactamase produced by Bacteroides fragilis. Antimicrob Agents Chemother (1983) 3.59
In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother (1988) 3.52
Induction of beta-lactamase by various beta-lactam antibiotics in Enterobacter cloacae. Antimicrob Agents Chemother (1980) 3.48
The decline in child mortality: a reappraisal. Bull World Health Organ (2000) 3.46
Plasmid-mediated penicillin beta-lactamases in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1976) 3.40
Variant of penicillinase mediated by an R factor in Escherichia coli. J Bacteriol (1970) 3.33
In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrob Agents Chemother (1987) 3.12
Determination of the ID50 values of antibacterial agents in agar. J Antibiot (Tokyo) (1978) 3.08
Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873. Antimicrob Agents Chemother (1984) 3.07
Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res (1993) 3.05
Drug resistance of enteric bacteria. XIV. Comparison of beta-lactamases in gram-negative rod bacteria resistant to alpha-aminobenzylpenicillin. Jpn J Microbiol (1968) 3.04
Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant. J Bacteriol (1987) 3.04
Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. J Biol Chem (1977) 3.02
In vitro and in vivo antibacterial activity of AB206, a new naphthyridine derivative. Antimicrob Agents Chemother (1980) 2.98
Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol (1994) 2.89
An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat Genet (1996) 2.89
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 2.84
Activity of beta-lactamase produced by Bacteroides fragilis against newly introduced cephalosporins. Antimicrob Agents Chemother (1980) 2.76
Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res (1999) 2.74
Beta-lactamase stability and antibacterial activity of cefmenoxime (SCE-1365), a novel cephalosporin. Antimicrob Agents Chemother (1981) 2.72
Biochemical properties of a penicillin beta-lactamase mediated by R factor from Bordetella bronchiseptica. Antimicrob Agents Chemother (1975) 2.70
STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci U S A (1996) 2.64
Comparative studies of penicillin-binding proteins in Pseudomonas aeruginosa and Escherichia coli. Eur J Biochem (1979) 2.58
Ischemic preconditioning increases adenosine release and 5'-nucleotidase activity during myocardial ischemia and reperfusion in dogs. Implications for myocardial salvage. Circulation (1993) 2.56
Phosphorylative inactivation of aminoglycosidic antibiotics by Escherichia coli carrying R factor. Science (1967) 2.55
Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res (2000) 2.54
Effect of N-formimidoyl thienamycin (MK0787) on beta-lactamases and activity against beta-lactamase-producing strains. Antimicrob Agents Chemother (1980) 2.53
Biochemical properties of a cephalosporin beta-lactamase from Pseudomonas aeruginosa. Jpn J Microbiol (1973) 2.50
Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother (2001) 2.46
Purification and some properties of a cephalosporinase from Proteus vulgaris. Antimicrob Agents Chemother (1981) 2.42
Estrogen activates telomerase. Cancer Res (1999) 2.41
Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci U S A (1991) 2.39
Inclusion of the transcervical approach in video-assisted thoracoscopic extended thymectomy (VATET) for myasthenia gravis: a prospective trial. Surg Endosc (2006) 2.39
Purification and properties of a cephalosporinase from Enterobacter cloacae. Antimicrob Agents Chemother (1980) 2.37
Norfloxacin resistance in a clinical isolate of Escherichia coli. Antimicrob Agents Chemother (1987) 2.33
Purification and properties of chromosomally mediated beta-lactamase from Citrobacter freundii GN7391. J Gen Microbiol (1980) 2.28
Properties of a new penicillinase type produced by Bacteroides fragilis. Antimicrob Agents Chemother (1982) 2.27
In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin. Chemotherapy (1990) 2.19
Plasmid-encoded metallo-beta-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Antimicrob Agents Chemother (2001) 2.17
Letter: Two beta-lactamase inhibitors produced by a streptomyces. J Antibiot (Tokyo) (1973) 2.16
Drug resistance to staphylococci. 3. Resistance to some macrolide antibiotics and inducible system. Jpn J Microbiol (1966) 2.13
Photocrosslinkable polysaccharides for in situ hydrogel formation. J Biomed Mater Res (2001) 2.12
In vitro activity of T-3761, a new fluoroquinolone. Antimicrob Agents Chemother (1992) 2.10
Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum. J Biol Chem (1977) 2.10
Biochemical properties of beta-lactamase produced by Legionella gormanii. Antimicrob Agents Chemother (1986) 2.10
Surface immunoglobulin-moieties on lymphoid cells. Exp Cell Res (1970) 2.09
In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin. Antimicrob Agents Chemother (1988) 2.08
Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res (1998) 2.08
Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant (2010) 2.05
In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrob Agents Chemother (1990) 2.05